Multicenter, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate Safety, Tolerability, and Efficacy of Ixekizumab in Patients From 6 to Less Than 18 Years of Age With Moderate-to-Severe Plaque Psoriasis
Phase of Trial: Phase III
Latest Information Update: 25 Jul 2018
At a glance
- Drugs Ixekizumab (Primary)
- Indications Plaque psoriasis
- Focus Registrational; Therapeutic Use
- Acronyms Ixora-peds
- Sponsors Eli Lilly
- 23 Apr 2018 Planned End Date changed from 3 Feb 2021 to 3 Jun 2021.
- 23 Apr 2018 Planned primary completion date changed from 3 Apr 2019 to 8 May 2020.
- 03 Apr 2017 Status changed from not yet recruiting to recruiting.